“Dovato” dolutegravir/lamivudine
฿11,000.00
Dovato (dolutegravir/lamivudine) is an innovative once-daily, single-tablet antiretroviral regimen specifically formulated for the effective treatment of HIV-1 infection. Combining two potent antiretroviral medications, Dovato simplifies HIV treatment while ensuring robust viral suppression. Ideal for those initiating treatment or switching from more complex regimens, Dovato offers proven effectiveness, ease of adherence, and a strong safety and tolerability profile.
Used to treat: Indications
- Treatment of HIV-1 infection in adults and adolescents weighing ≥40 kg.
- Recommended as an initial HIV therapy or for patients with stable viral suppression considering regimen simplification.
Benefits
- Effective Viral Suppression: Clinically proven to maintain an undetectable viral load (<50 copies/mL), thereby preventing HIV transmission (Undetectable = Untransmittable, U=U).
- Simplicity & Improved Adherence: Single tablet taken once daily significantly reduces pill burden, enhancing treatment adherence and patient convenience.
- Strong Safety Profile: Demonstrates fewer side effects and improved tolerability compared to multi-pill or older HIV treatment options.
- Minimal Drug Interactions: Suitable for use alongside many common medications, with minimal need for complex dosage adjustments.
- Long-term Efficacy: Clinically validated to sustain viral suppression with only two drugs, reducing overall exposure to antiretroviral agents.
Dovato (ViiV Healthcare) is acclaimed for its streamlined approach to HIV management, offering a cost-effective alternative to three-drug regimens like Biktarvy by utilizing only two drugs, thus potentially reducing overall treatment costs and drug exposure. However, it is still significantly more expensive than Biktarvy due to its licensing & patent protection and cost of distribution.
